C
Colin Ray
Researcher at University of Copenhagen
Publications - 35
Citations - 1064
Colin Ray is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Lactose & Whey protein. The author has an hindex of 14, co-authored 34 publications receiving 751 citations. Previous affiliations of Colin Ray include Royal Institute of Technology & Arla Foods.
Papers
More filters
Journal ArticleDOI
Control of Maillard Reactions in Foods: Strategies and Chemical Mechanisms
Marianne N. Lund,Colin Ray +1 more
TL;DR: Recent advances in strategies for controlling the Maillard reaction and subsequent downstream reaction products in food systems are critically reviewed.
Journal ArticleDOI
Lactose-Hydrolyzed Milk Is More Prone to Chemical Changes during Storage than Conventional Ultra-High-Temperature (UHT) Milk
Therese Jansson,Morten Rahr Clausen,Ulrik Kræmer Sundekilde,Nina Eggers,Steffen Nyegaard,Lotte Bach Larsen,Colin Ray,Anja Sundgren,Henrik J. Andersen,Hanne C. Bertram +9 more
TL;DR: Observations indicate more favorable conditions for Maillard and subsequent reactions in lactose-hydrolyzed milk compared to conventional UHT milk stored at ambient temperature and it is postulated that proteolytic activity from the lactase-enzyme preparation may be responsible for the observed higher levels of free amino acids.
Journal ArticleDOI
Sulfonimidamides as sulfonamides bioisosteres: rational evaluation through synthetic, in vitro, and in vivo studies with γ-secretase inhibitors.
Fernando Sehgelmeble,Juliette Janson,Colin Ray,Susanne Rosqvist,Susanne Gustavsson,Nilsson Linda I,Alexander Minidis,Jörg Holenz,Didier Rotticci,Johan Lundkvist,Per I. Arvidsson,Per I. Arvidsson,Per I. Arvidsson +12 more
TL;DR: Detailed in vitro and in vivo profiling reveal that the sulfonimidamide motif imparts desirable properties such as decreased lipophilicity and plasma protein binding, accompanied by increased solubility, which support a wider use of this unique functional group in the design of new pharmacologically active agents.
Journal ArticleDOI
Substituted 7-amino-5-thio-thiazolo[4,5-d]pyrimidines as potent and selective antagonists of the fractalkine receptor (CX3CR1)
Sofia Karlström,Gunnar Nordvall,Daniel Sohn,Hettman Andreas,Dominika Turek,Kristofer Åhlin,Annika Kers,Martina Claesson,Can Slivo,Yvonne Lo-Alfredsson,Carl Petersson,Galina Bessidskaia,Per H. Svensson,Tobias Rein,Eva Jerning,Åsa Malmberg,Charlotte Ahlgen,Colin Ray,Lauri Vares,Vladimir Ivanov,Rolf Johansson +20 more
TL;DR: The structure-activity relationships showed that a leucinol moiety attached to the core-structure in the 7-position together with α-methyl branched benzyl derivatives in the 5-position displayed promising affinity, and selectivity as well as physicochemical properties, as exemplified by compounds 18a and 24h.
Patent
Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
Per I. Arvidsson,Erwan Arzel,Jeremy N. Burrows,Martina Claesson,Colin Ray,Tobias Rein,Didier Rotticci,Peter Söderman +7 more
TL;DR: In this article, the present invention relates to new compounds of formula (I) Wherein X is or Y; as a free base or a pharmaceutically acceptable salt, solvate or solvates of salt thereof, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.